{"id":801,"date":"2021-02-16T06:03:25","date_gmt":"2021-02-16T06:03:25","guid":{"rendered":"https:\/\/www.l2mtech.de\/?page_id=801"},"modified":"2023-04-30T05:05:49","modified_gmt":"2023-04-30T05:05:49","slug":"news-events","status":"publish","type":"page","link":"https:\/\/www.l2mtech.de\/?page_id=801","title":{"rendered":"News & Events"},"content":{"rendered":"

[vc_row][vc_column][vc_column_text]\"\"<\/p>\n

L2Mtech GmbH Receives CE Mark Approval on
\n6 (SIX) products for Cardiovascular and
\nEndovascular Applications
\nCE Mark Approval for LimusTrackTM; LomiFlowTM; PearlFlowTM; PearlFlow NSTM; FlexiTrack 018TM and
\nFlexiTrack 035TM for Cardiovascular and Endovascular Applications
\nBONN, NRW, GERMANY, February 11, 2021 \/EINPresswire.com\/ — L2Mtech GmbH Founder and
\nCEO Lalit Mamtani said \u2018\u2018We are very excited to have been awarded our first CE Mark on six
\nproducts, CE Mark approval represents a key milestone for L2Mtech GmbH and is a testament to
\nthe efficacy and safety of our innovative technology products for Cardiovascular and
\nEndovascular applications.\u201c
\nWe now prepare to commercially launch the products in all markets where the CE Mark is
\nrecognized. With introduction of our innovative technology products in markets, we will be able
\nto expand treatment options for the benefit of many millions of patients with coronary and
\nperipheral artery disease around the world.
\nL2Mtech GmbH has announced the award of its first CE Mark approval on Six (6) products:
\nLimusTrackTM : Sirolimus Coated Cobalt Chromium Stent with biodegradable polymer for the
\ntreatment of coronary artery disease, de novo lesions, restenosis lesions.
\nLomiFlowTM : Paclitaxel Coated balloon catheter for the treatment of coronary artery disease,
\nsmall vessels, dilatation of de novo lesions, in-stent restenosis (ISR) cases .
\nPearlFlowTM : Paclitaxel Coated balloon catheter for the treatment of peripheral arterial disease,
\nPTA, dilatation of stenotic segments or lesions in peripheral arteries.
\nPearlFlow NSTM : Self-Expanding Nitinol Stent System for the treatment of peripheral arterial
\ndisease, de novo lesions, lesions in femoropopliteal arteries.
\nFlexiTrack 018TM : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial
\ndisease, dilatation of lesions in femoral, popliteal, tibial arteries.
\nFlexiTrack 035TM : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterialdisease, dilatation of lesions in the SFA, femoral arteries.
\nAbout L2Mtech
\nFounded in 2017, L2Mtech GmbH is a privately-owned multinational medical device company
\nheadquartered at Bonn, Germany. L2Mtech specializes in design, development, manufacture
\nand commercialization of medical devices that are used by healthcare establishments globally.
\nL2MTech will provide interventional physicians with innovative vascular devices including Drug
\nEluting Balloon manufactured in Europe. Our Core mission is to build a product portfolio focused
\non minimally invasive treatment for patients with cardiovascular, endovascular and vascular
\nartery disease. For further information, please visit : www (dot) L2MTech (dot) de
\nAdmin
\nL2Mtech GmBh
\n+49 228 94730761
\nadmin@L2Mtech.de
\nThis press release can be viewed online at: https:\/\/www.einpresswire.com\/article\/535441720
\nEIN Presswire’s priority is source transparency. We do not allow opaque clients, and our editors
\ntry to be careful about weeding out false and misleading content. As a user, if you see something
\nwe have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,
\nEveryone’s Internet News PresswireTM, tries to define some of the boundaries that are reasonable
\nin today’s world. Please see our Editorial Guidelines for more information.
\n\u00a9 1995-2021 IPD Group, Inc. All Right Reserved.[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][vc_column_text] L2Mtech GmbH Receives CE Mark Approval on 6 (SIX) products for Cardiovascular and Endovascular Applications CE Mark Approval for LimusTrackTM; LomiFlowTM; PearlFlowTM; PearlFlow NSTM; FlexiTrack 018TM and FlexiTrack 035TM for Cardiovascular and Endovascular Applications BONN, NRW, GERMANY, February 11, 2021 \/EINPresswire.com\/ — L2Mtech GmbH Founder and CEO Lalit Mamtani said \u2018\u2018We are very excited<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/www.l2mtech.de\/index.php?rest_route=\/wp\/v2\/pages\/801"}],"collection":[{"href":"https:\/\/www.l2mtech.de\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.l2mtech.de\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.l2mtech.de\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.l2mtech.de\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=801"}],"version-history":[{"count":11,"href":"https:\/\/www.l2mtech.de\/index.php?rest_route=\/wp\/v2\/pages\/801\/revisions"}],"predecessor-version":[{"id":834,"href":"https:\/\/www.l2mtech.de\/index.php?rest_route=\/wp\/v2\/pages\/801\/revisions\/834"}],"wp:attachment":[{"href":"https:\/\/www.l2mtech.de\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=801"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}